MDedge Hematology and Oncology | MDedge Hematology and Oncology

Chronicles of cancer: A history of mammography

Hepatitis screening now for all patients with cancer on therapy

Sharon Worcester

All patients with cancer who are candidates for systemic anticancer therapy should be screened for hepatitis B virus (HBV) infection prior to or at the start of therapy, according to an updated provisional clinical opinion (PCO) from the American Society of Clinical Oncology.

Latest News

August 13, 2020

Determining cause of skin lesions in COVID-19 patients remains challenging

August 13, 2020

Heidi Splete

Heidi Splete

August 13, 2020

MDedge Hematology and Oncology

August 13, 2020

Persistent hair loss after radiation improved with minoxidil

August 13, 2020

Veronica Hackethal, MD

Veronica Hackethal, MD

August 13, 2020

MDedge Hematology and Oncology

August 13, 2020

Since COVID-19 onset, admissions for MI are down, mortality rates are up

August 13, 2020

Ted Bosworth

Ted Bosworth

August 13, 2020

MDedge Hematology and Oncology

Blood & Cancer Podcast

B&C Podcast Shownotes

ISTH 2020: VTE in COVID-19, bevacizumab in HHT, and more

Hanny Al-Samkari, MD, joins the podcast to discuss thrombosis in COVID-19 and lung cancer patients as well as the use of bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). Dr. Al-Samkari presented three studies on these topics at the virtual ISTH 2020 Congress.

Conference Coverage

August 11, 2020

Sintilimab scintillates in first-line nonsquamous NSCLC

August 11, 2020

Liam Davenport

Liam Davenport

August 11, 2020

IASLC World Conference on Lung Cancer

MDedge Hematology and Oncology

August 11, 2020

Chemo-free management of mesothelioma on horizon

August 11, 2020

Liam Davenport

Liam Davenport

August 11, 2020

IASLC World Conference on Lung Cancer

MDedge Hematology and Oncology

August 10, 2020

Artificial intelligence matches cancer genotypes to patient phenotypes

August 10, 2020

Alan P. Lyss, MD

Alan P. Lyss, MD

August 10, 2020

AACR: American Association for Cancer Research

MDedge Hematology and Oncology

MD Hematology Oncology MD-IQ

Tumor factors in epithelial ovarian cancer outcomes

Imaging for detection of minimal residual disease in multiple myeloma

Stereotactic ablative radiotherapy for NSCLC

Standard approaches in peripheral T cell lymphoma treatment

Fast Facts Friday: August 7, 2020

Diagnose It: August 8, 2020

COVID-19: Heme/Onc

August 7, 2020

Study: Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19

August 7, 2020

Sharon Worcester

Sharon Worcester

August 7, 2020

AACR: COVID-19 and Cancer

MDedge Hematology and Oncology

July 31, 2020

OK to treat many cancer patients despite pandemic, says ESMO

July 31, 2020

Roxanne Nelson, RN, BSN

Roxanne Nelson, RN, BSN

July 31, 2020

MDedge Hematology and Oncology

July 30, 2020

Higher death rate seen in cancer patients with nosocomial COVID-19

July 30, 2020

Sharon Worcester

Sharon Worcester

July 30, 2020

AACR: COVID-19 and Cancer

MDedge Hematology and Oncology

July 29, 2020

Hematologic manifestations of COVID-19

July 29, 2020

Alan P. Lyss, MD

Alan P. Lyss, MD

July 29, 2020

MDedge Hematology and Oncology

News from the FDA/CDC

August 10, 2020

FDA approves first liquid biopsy/NGS test for lung cancer

August 10, 2020

Roxanne Nelson, RN, BSN

Roxanne Nelson, RN, BSN

August 10, 2020

MDedge Hematology and Oncology

August 6, 2020

FDA approves belantamab in relapsed/refractory multiple myeloma

August 6, 2020

Zosia Chustecka

Zosia Chustecka

August 6, 2020

MDedge Hematology and Oncology

July 31, 2020

FDA approves triple drug combo for melanoma

July 31, 2020

Nick Mulcahy

Nick Mulcahy

July 31, 2020

MDedge Hematology and Oncology

MDedge Roundtables

Ovarian Cancer: Updates in Patient Management and Treatment Selection

Small Cell Lung Cancer Diagnosis & Treatment

CLL/SLL Roundtable: Updates On Patient Management

Classic Hodgkin Lymphoma

Peripheral T-Cell Lymphoma

Policy & Practice

August 13, 2020

Pandemic effect: Telemedicine is now a ‘must-have’ service

August 13, 2020

Richard Franki

Richard Franki

August 13, 2020

MDedge Hematology and Oncology

August 10, 2020

Pandemic hampers reopening of joint replacement gold mine

August 10, 2020

Bernard J. Wolfson, Kaiser Health News

Bernard J. Wolfson, Kaiser Health News

August 10, 2020

MDedge Hematology and Oncology

August 6, 2020

When you see something ...

August 6, 2020

William G. Wilkoff, MD

William G. Wilkoff, MD

August 6, 2020

MDedge Hematology and Oncology

August 4, 2020

The best and worst states for health care in 2020

August 4, 2020

Richard Franki

Richard Franki

August 4, 2020

MDedge Hematology and Oncology

Opinion

August 13, 2020

Action and awareness are needed to increase immunization rates

August 13, 2020

Kristina A. Bryant, MD

Kristina A. Bryant, MD

August 13, 2020

MDedge Hematology and Oncology

August 6, 2020

When you see something ...

August 6, 2020

William G. Wilkoff, MD

William G. Wilkoff, MD

August 6, 2020

MDedge Hematology and Oncology

July 31, 2020

COVID-19–related skin changes: The hidden racism in documentation

July 31, 2020

Graeme M. Lipper, MD

Graeme M. Lipper, MD

July 31, 2020

MDedge Hematology and Oncology

July 30, 2020

Are you SARS-CoV-2 vaccine hesitant?

July 30, 2020

William G. Wilkoff, MD

William G. Wilkoff, MD

July 30, 2020

MDedge Hematology and Oncology

MD Hematology Oncology ClinicalEdge

Determining cause of skin lesions in COVID-19 patients remains challenging

Since COVID-19 onset, admissions for MI are down, mortality rates are up

Elotuzumab-based therapy may benefit post-transplant response in multiple myeloma

BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients

Conference ReCAP

HCC and Liver Cancer ASCO 2020

Metastatic Breast Cancer ASCO 2020

Non–Small Cell Lung Cancer ASCO 2020

Ovarian Cancer ASCO 2020

Board Review Questions

Autoimmune Hemolytic Anemia

Gastrointestinal Stromal Tumors

Testicular Cancer

Management of Advanced Melanoma

Castration-Resistant Prostate Cancer

Transfusion Reactions (part 2)